Clinical Trial Update: Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study evaluating the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16; the trial has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Tick-borne Encephalitis | Phase 2 | Status: COMPLETED